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Update in the mechanisms of allergen-specific immunotheraphy
Abstract
Allergic diseases represent a complex innate and adoptive immune response to natural environmental
allergens with Th2-type T cells and allergen-specific IgE predominance. Allergen-specific
immunotherapy is the most effective therapeutic approach for disregulated immune response towards
allergens by enhancing immune tolerance mechanisms. The main aim of immunotherapy is the
generation of allergen nonresponsive or tolerant T cells in sensitized patients and downregulation of
predominant T cell- and IgE-mediated immune responses. During allergen-specific immunotherapy, T
regulatory cells are generated, which secrete IL-10 and induce allergen-specific B cells for the
production of IgG4 antibodies. These mechanisms induce tolerance to antigens that reduces allergic
symptoms. Although current knowledge highlights the role of T regulatory cell-mediated
immunetolerance, definite mechanisms that lead to a successful clinical outcomes of allergen-specific
immunotherapy still remains an open area of research.
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INTRODUCTION
The main role of the immune system is the ability to distinguish 
self from non-self while still responding to and neutralizing 
pathogens. The physiopathology of immune tolerance-related 
diseases, such as allergy, asthma or autoimmune diseases is 
complex and influenced by several factors. These include genet-
ic susceptibility, the nature of the antigen that initiates the dis-
ease (antigen dose, time of exposure, route of exposure, and its 
structural characteristics) and possible co-exposure with innate 
immune response stimulating substances, such as infections 
and flora bacteria.1
Since allergy is a predominantly Th2 type of immune disorder, 
one of the essential ways to overcome the deviated immune re-
sponse has been allergen-specific immunotherapy (SIT) that 
involves repeated administration of the sensitizing allergens by 
subcutaneous injection or mucosal route. The induction of pe-
ripheral tolerance towards the responsible allergen is the main 
target in allergen-SIT. After successful immunotherapy, aller-
gen-specific T regulatory cells (Treg) are generated and they 
suppress proliferative and cytokine responses against allergens.2 
In addition, antibody class-switching occurs in B cells that se-
crete allergen-specific IgG4 instead of IgE which has blocking 
capacity inhibiting binding between allergen and IgE on mast 
cells and basophils. This review focuses on mechanism of aller-
gen-SIT and discusses the current approaches in clinical and 
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research perspective of immune tolerance induction in allergic 
disorders.
IMMUNE RESPONSE TO ALLERGENS
Loss of tolerance to certain allergens such as, aeroallergens, 
foods and insect venom, leads to induction of type I hypersen-
sitivity reactions. The type of immune response influenced by 
several factors including genetic susceptibility, the nature of an-
tigen which initiates the disease (antigen dose, time of exposure, 
route of exposure, and structural characteristics), and challenge 
with infections and bacteria.3 Under these complex stimulus, 
navie T cells activated by professional antigen-presenting cells 
(APC) and differentiate into Th1, Th2, Th17 or Th9 cells. For 
atopic disease, the Th2 arm of immune response is responsible 
for immunopathology and clinical scene. Once Th2 response is 
established, the mechanism of allergic disease is further divid-
ed into two main phases: first sensitization, and development 
of memory and later followed by effector phase and tissue inju-
ry. In the sensitization phase, allergen-specific CD4+Th2 cells 
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produce IL-4 and IL-13, which induce B cell class-switch into 
the antibody isotypes of ε immunoglobulin heavy chain and 
the production of allergen-specific IgE antibody. Later, allergen-
specific IgE, binds to high affinity receptor for IgE (FcεRI recep-
tors) on the surface membrane of mast cells and basophils. 
These series of activations lead to the sensitization of the pa-
tients to a specific allergen. Re-exposure to the sensitized aller-
gen leads to the aggregation of receptor-bound IgE molecules 
and results in the activation and mediator release that lead to 
the development of clinical symptoms of type I hypersitivity re-
actions.4,5
Immediate reactions are followed by late phase reactions with 
the activation of T cells by continuous presence of allergens. 
Once allergen-specific CD4+Th2 cells are activated, they produce 
IL-4, IL-5, IL-9, and IL-13, which play crucial role in the mainte-
nance of high allergen-specific IgE levels, stimulate eosinophil 
progenitors in the bone marrow, induce inflammatory cell in-
flux into inflamed tissue, and induce production of mucus and 
smooth muscle contraction.3 These events require T cell activa-
tion and peripheral T cell tolerance prevents formation of atop-
ic immunopathology in healthy subjects. A continuous interac-
tion with migrating T cells and resident tissue cells takes place 
and other subsets such as Th1 cells, Th9 cells, Th17 cells, and 
Th22 cells also play important roles.6-8
ROLE OF TH17 AND TH22 CELLS ON ALLERGIC 
DISORDERS
Th17 cells represent a newly discovered subset of T lympho-
cytes and are involved in the pathogenesis of several immune-
mediated disorders. IL-17, IL-6, TNF-α, and IL-22 are signature 
cytokines of Th17 cells and play important roles on tissue pa-
thology in autoimmune disorders as well as allergic disease.9 
Recent studies showed the importance of allergen-specific Th17 
cells in humans.10 IL-17 is essentially important for the recruit-
ment of neutrophils and expressed in bronchial biopsies, bron-
choalveolar lavage fluid and sputum of patients of asthma.11 IL-
17A and IL-17F are negative regulators of antigen driven Th2 
response.12,13 It has also been demonstrated that anti-IL-17 re-
duces neutrophilic infiltration in experimental murine asthma 
models.14 Furthermore, IL-17 increases eosinophilic infiltration 
and recruitment/survival of airway macrophages.12 Patients with 
allergic rhinitis revealed high frequency of IL-17-producing T 
cells.15 Taken together, IL-17 contribute to the differentiation 
and activation of allergen-specific Th2 cells, influx of eosino-
phils to target organs, and serum IgE production that provide 
important clues in the role of Th2 driven allergic response.16
Similar to Th17 cells, Th22 cells were rarely found in PBMCs, 
while they were clearly detected in T cell population isolated 
from skin of patients with psoriasis, atopic eczema and allergic 
contact dermatitis.17 Furthermore, IL-22 synergizes with IL-17 
in the induction of proinflammatory cytokines in human bron-
chial epithelial cells18 and colonic myofibroblasts.19
DENDRITIC CELLS AS KEY PLAYERS IN ALLERGIC 
INFLAMMATION
Dendritic cells (DCs) play a crucial role for detecting innate 
pathogens and triggering adaptive immune response. Within 
the subtypes of DCs, plasmacytoid DCs (pDCs) take attention 
by their surface phenotype, tissue localization, cytokine secre-
tion, and antigen-presentation function,20 and keep important 
role in the initiation and regulation of immune response and 
immune tolerance.21 The maturation period influences the role 
of DCs in the tolerance formation. Especially, semi-mature DC 
induce tolerance in the immune system, whereas matured DCs 
mediate expression of interferon (IFN)-γ producing T cells.22 
Taken together, distrubiton of DC subsets and their maturation 
stage seems to be essential in tolerance induction to certain an-
tigens.
Murine oral mucosal dendritic cells (mDCs) express CD11b+/
CD11c-/+ at the mucosal/submucosal junction zone, whereas 
langerhans cells epress CD207+ within the mucosal epithelium 
and pDCs express B220+/120G8+ in the submucosal region. In a 
study on sublingual application of OVA, a total clearence of OVA 
within 15-30 minutes by CD11b+/CD11c-/+ mDCs was shown.23 
It seems however that these murine studies are not fully rele-
vant to human in vivo stimulation. In humans, oral mucosal 
Langerhans cells (oLCs) represent the predominant DC popu-
lation, however pDCs are virtually absent in oral mucosa. oLCs 
constitutively express high affinity receptor for IgE, which is ab-
sent in classical epidermal Langerhans cells. FcεRI expression 
is seen during early differentiation period of Langerhans cells 
as well as other DCs and it possesses a pro-tolerogenic charac-
ter. Studies clearly demonstrate that oLCs of atopic individuals 
show increased expression of FcεRI that cooperates with IgE.24 
This strategic location of oLCs at suprabasal epithelium layer 
and increased expression of FcεRI may facilitate binding and 
processing of allergens in sublingual immunotheraphy (SLIT) 
period.
ROLE OF REGULATORY T CELLS IN IMMUNE TOLERANCE 
TO ALLERGENS
The importance and functions of Treg cells to induce tolerance 
have been explicitly studied during the last 15 years. The major 
role of Treg cells in immune tolerance was clarified in murine 
studies directly or adoptive transfer of Treg cells. They prevent 
or cure numerous T-cell-mediated disease models, including, 
asthmatic lung inflammation, autoimmune diseases and al-
lograft rejection, by achieving immune tolerance to responsible 
allergens, self antigens or alloantigens.25 On the other hand, 
chronic absence or imperfect function of Treg cells may lead a 
series of immune dysfunction disease, such as hyper IgE syn-
Mechanism of ImmunotherapyAAIR 
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drome, hyper eosinophilia and autoimmunity in humans, which 
is normal with appropriate function of Treg cells.26 For an easy 
understanding, Treg cells may be divided into two main sub-
groups; The naturally occurring forkhead box P3 (Foxp3)+CD4+
CD25+ regulatory T cells (will be referred as CD4+CD25+Treg 
cells)27, which develop in the thymus and are present in birth, 
and the other is inducible Treg cells, which is generated in the 
periphery under various tolerogenic conditions. Especially, the 
IL-10-producing T regulatory type 1 (Tr1) cells have been shown 
to play a key role in allergen tolerance, and can be induced by 
allergen-SIT in humans.28-31 With recent studies, it is well estab-
lished that Foxp3 acts as master switch transcription factor for 
Treg cell development and function.32 Foxp3 mutations in the 
mice leads spontaneous development of allergic airway inflam-
mation, hyper IgE syndrome, eosinophilia as well as autoim-
mune disease.26 Mutations in Foxp3 gene in humans leads for-
mation of X-linked immune dysregulation polyendocrinopathy 
enteropathy syndrome (IPEX), hyper IgE syndrome and ecze-
ma.26 A dysregulation of disease-causing effector T cells is ob-
served in atopic dermatitis lesions, in association with an im-
paired CD4+CD25+FoxP3+T-cell infiltration, despite the expres-
sion of type 1 regulatory cells in the dermis.33 Apart from these, 
main subsets of Treg cells, several other T cells with regulatory 
function has been described. Among them, suppressor capaci-
ty in vitro revealed CD8+ CD28- T cells, which are able to pre-
vent up-regulation of B7 molecules induced by Th cells on pro-
fessional APCs34 and play role in oral tolerance.35 TCRαβ+CD4–
CD8– double-negative Treg cells have been shown to suppress 
Ag-specific immune responses mediated by CD8+ and CD4+ T 
cells in humans and mice.36 NKreg cell also has the capacity to 
suppress antigen specific T cell response.37 It has recently been 
demonstrated that, the transforming growth factor-beta (TGF-
beta) induced the expression of the Runt-related transcription 
factors RUNX1 and RUNX3 in CD4+ T cells.6 This induction 
seems to be a prerequisite for the binding of RUNX1 and RUNX3 
to three putative RUNX binding sites in the FOXP3 promoter. 
Further, in this study it was shown that RUNX transcription fac-
tors act as a molecular link in TGF-beta-induced Foxp3 expres-
sion in inducible Treg cell differentiation and function.
Tr1 cells are dominant type of T cell subset in healthy individ-
uals. Studies clearly show that, allergen-specific Tr1 cells are 
predominant in healthy individuals to prevent unwanted im-
mune response to nonpathogenic environmental antigens such 
as house dust mite, birch pollen, bee venom and food antigens 
(hazelnut, pear) which lead to allergy.38,39 Healthy and allergic 
individuals denote three different allergen-specific T cell sub-
types as Th1, Th2 and Tr1 in different ratios.39 The imbalance be-
tween Th2 and Tr1 cells and depending the dominant subset 
may conduce allergy development or recovery from allergy. Pe-
ripheral T cell tolerance to venom allergen is an appropriate 
model for high dose tolerance to allergens in humans. During 
beekeeping season repeated exposure of non-allergic healthy 
beekeepers to bee venom antigens denote an efficient model to 
apprehend mechanisms of immune tolerance to bee venom al-
lergens.40 During the exposure to venom allergen, venom spe-
cific IL-10-secreting Tr1 cells show a switch from allergen-spe-
cific Th1 and Th2 cells. This leads to suppression of allergen-
specific undesired immune response by Th1 and Th2 cells. This 
immunomodulator response persist as long as venom exposure 
continuous and returns to the initial level within 2-3 months af-
ter the end of the beekeeping season and stimulation of hista-
mine receptor 2 on Th2 cells by histamine suppresses allergen-
stimulated T cells and enhance IL-10 production as an addi-
tional immune tolerance mechanism. Supporting these find-
ings, non-allergic beekeepers have approximately 1,000 times 
higher allergen-specific IgG4 versus allergen-specific IgE ratio 
compared to bee venom allergic individuals.41 Another tolerance 
model with cat allergen also showed elevated levels of allergen-
specific IgG4 levels after exposure to high dose cat allergen.42
THERAPEUTIC APPROACHES THAT USE REGULATORY 
T-CELLS
With the knowledge of suppressive and immunomodulatory 
capacity of inducible or constitutive Treg cells, novel treatment 
strategies for T-cell mediated disease such as transplantation 
rejection, autoimmunity and allergy are being developed. The 
curative and preventive effect on disease conditions experienced 
by both adaptive transfer of regulatory T cells or their induction 
by immunomodulators in vivo are under consideration. Com-
pared to conventional treatment strategies, their antigen-spe-
cific suppressor capacity as well as long-lasting antigen-specific 
regulation in vivo with a limited side effects were reported.43 
Recent studies on immunomodulators that is targeting to en-
hance or suppress the numbers and functions of Treg cells, are 
rapamycin,44 co-stimulatory blockage,45 non-mitogenic anti-CD3 
mAbs,46 T cell depletion47 and anti-TNF-α mAb48 (Table).49-75
Specifically expanded Treg cells can be targeted to allergen or 
an autoantigen expressed in the inflamed organs in murine 
models.76 Further, the transfer of this organ specific Treg cells 
can suppress an ongoing disease.77 These studies aimed for a 
successful therapeutical approach by targeting the Treg cell 
arm of immune tolerance against allergens, autoantigens or 
transplantation antigens. Several investigations are ongoing for 
adoptive transfer of Treg cells or small compounds aimed to in-
duce Treg cells in the tissues.76 Other therapeutical approaches 
such as allergen-SIT, treatment with glucocorticoids, and beta-
2 agonists seem to particially function by promoting the num-
bers and activity of IL-10-secreting Tr1-like cells.78-80
SUBCUTANEOUS OR SUBLINGUAL ROUTES OF 
ALLERGEN-SPECIFIC IMMUNOTHERAPY
Allergen-specific immunotherapy, repeated administration of 
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the sensitizing allergens by subcutaneous injection or mucosal 
route, has been used nearly 100 years ago by Noon and Freeman 
to grass polen allergic patiens with grass polen extracts. Clinical 
and experimental studies clearly show that SLIT is relatively 
safe method compared to subcutaneous immunotheraphy 
(SCIT) for the treatment of allergic disease,81,82 however the 
mechanisms of SLIT are less understood and its efficacy seems 
to be less than SCIT.83-85 Oral mucosal tissue has a natural tolero-
genic character without any acute inflamation in spite of high 
bacterial colonization and good wound healing without scar 
development. Lack of inflammatory cells around mucosal tis-
sue and high permeability for allergens suggests a way of action 
for sublingual allergen immunotherapy.86 The first step of SLIT 
is to uptake an allergen by Langerhans cells-specialized den-
dritic cells24 within the oral mucosa via high affinity surface IgE 
receptors.87 This leads to secretion of IL-10 and induction of T 
cells with a regulatory phenotype in vitro.88 Although clinical 
trails demonstrate treatment efficacy of SCIT in allergic asth-
ma, allergic rhinitis, and stinging insect hypersensitivity as well 
as aero-allergen-induced atopic dermatitis such as reduction of 
allergic symptoms and drug intake, there is a risk of serious ad-
verse reactions which can be classified in two categories: local 
reactions, which can appear as erythema, pruritus and swelling 
at the injection site; and systemic reactions can range in severi-
ty from mild to very severe life-threatening anaphylaxis.89-91
MECHANISMS OF ALLERGEN-SPECIFIC 
IMMUNOTHERAPY
The primary purpose of allergen-SIT is the induction of periph-
eral T cell tolerance to allergens.28-31,39,92 Once peripheral T cell 
tolerance is triggered, allergen-specific Treg cells produce ela-
veted levels of IL-10 and TGF-β which are anti-inflammatory 
cytokines.29-31,38 The cytokines secreted from Treg cells mostly 
depend on the type of organ they dwell and the path in which 
they are stimulated. Experimental and clinical data revealed 
Table. Novel immunomodulatory approaches for allergen-specific immunotherapy
Type of the vaccine/approach Description and mechanism
Fusion of major allergens50 Major allergens (Api m 1, Api m2) are fused and expressed as a single recombinant protein. IgE binding is at-
tenuated, T cell reactivity is preserved. Preventive effect on generation of IgE is demonstrated in mice.
Chimeric allergens51 Fragments of major allergens (Api m 1, Api m2, Api m3) are fused and expressed as a single protein. IgE bind-
ing is attenuated, T cell reactivity is preserved. Preventive effect on generation of IgE is demonstrated in 
mice.
Fragments52 Major allergen (Bet v 1) is divided to non IgE binding fragments. IgE binding is attenuated T cell reactivity is 
preserved.
Peptides of major allergens53-60 Non IgE binding T cell epitope peptides (Fel d 1, Api m 1) have been used in cat and bee venom allergy.
Polymers of major allergens52 Major allergen (Bet v 1) is trimerized.
Mast cell, basophil degranulation is attenuated, T cell reactivity is preserved in vitro.
Unrefolded native or recombinant allergens61-63 Major recombinant allergens (Api m 1, Bet v 1) are not refolded to the native conformation. This decreases or 
abolishes IgE binding, but preserves T cell reactivity.
Mixture of several major recombinant allergens49 A mixture of five recombinant grass pollen allergens (Phl p 1, Phl p 2, Phl p 5a, Phl p 5b, Phl p 6) reduced 
symptoms and need for symptomatic medication in grass pollen allergic patients
GpG oligonucleotide-conjugated allergens64 Major allergen (Amb a 1) is bound to a toll-like receptor 9-triggering CpG oligonucleotide. In this way allergen 
and innate immune response stimulating agent are expressed in one molecule.
Monophosphoryl Lipid A65-67 Four preseasonal injections with grass or tree formulations significantly reduced rhinoconjunctivitis symp-
toms and medication use, and elevated allergen-specific immunoglobulin G.
Allergens coupled to virus-like particles68 Der p 1 peptides coupled to highly repetitive virus capside-like recombinant particles induced high specific 
IgG titres.
Combination of conventional SIT with anti IgE69 Anti-IgE mAb pretreatment enhances the safety of SIT for allergic rhinitis. Its role on long term efficacy is still 
under investigation.
Intralymphatic vaccination70,71 Allergen-SIT vaccines administered directly into a lymph node. The aim is to deliver high amounts of aller-
gens into secondary lymphatic organs.
Targeting FcγRII72,73 Fusion of allergens with human Fc has been reported to inhibit allergen-induced basophil and mast cell de-
granulation by crosslinking Fc and Fc RI receptors.
MAT vaccines74,75 The fusion of transactivator of transcription (Tat) peptide to both truncated Ii (invariant chain) and allergens is 
able to target antigens to the nascent MHC II molecules in the trans-golgi compartment.
SIT, specific immunotherapy
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that Treg cells may secrete only IL-10, IL-10, and IFN-γ or IL-10 
and TGF-β.25,39,93-96 Treg cells do not only suppress Th2 immune 
response and peripheral tolerance is achieved with multiple 
mechanism to overcome and suppress allergic inflammation. 
The other roles of Treg cells are suppression of dendritic cells 
and by this, enhance the generation of effector or induction of 
dendritic cells that support the generation of Treg cells,97-99 sup-
pression of Th1 and Th2 cells,100 suppression of allergen-specif-
ic IgE and induction of IgG4 and/or IgA,101 suppression of mast 
cells, basophils and eosinophils,102 interaction with resident cells 
and remodelling.103,104 In SCIT both circulating30 and mucosal 
Tregs105 form and these Tregs may induce B cells to produce 
protective IgG4 antibodies106 and IgA2 antibodies.107 Prolifera-
tive response of T cell clones are also inhibited by IgG4 anti-
bodies through prevention of IgE-faciliated allergen binding to 
B cells and subsequent presentation to allergen-specific T cell 
clones108 (Figure).
Mucosal immunotherapy to house dust mite, birch polen or 
food antigens leads to induction of Tr1 cells, which secrete IL-
10 and TGF-β.31 Treg cells stimulated with toll-like receptors 
produce IL-10 and IFN-γ.94 After venom allergen-SIT, there is a 
induction of Tr1 cells producing only IL-10.109 Overall, it is obvi-
ous that allergen-SIT has a modulatory effect on allergen-spe-
cific T cells. In the mechanism of succesful allergen-SIT, shift in 
Th2 immunity to Th1 immune response is observed in periph-
eral blood,110,111 allergic rinitis112 and cutaneous late phase re-
sponses.110 One of the studies carried on patients with allergic 
rihinitis revealed that after grass pollen immunotherapy, Foxp3+
CD25+ and Foxp3+CD4+ cells numbers were found to be in-
creased in the nasal mucosa.105 Also after this allergen-SIT, IL-
Figure. Mechanisms of allergen-specific immunotherapy. Both subcutaneous and sublingual SITs first affect the regional antigen-presenting cell, namely the local 
dendritic cell subset in the place of administration and draining lymph nodes. Although in vivo mechanisms are not clearly known, these dendritic cells induce Treg 
(CD4+CD25+FoxP3+) cells and Tr1 cells (IL-10+). Treg cells and regulatory cytokines (such as interleukin-10 (IL-10) and transforming growth factor-β, TGFβ) may con-
tribute to the control of allergen-induced immune responses in several different ways. TReg cells utilize multiple suppressor factors to regulate the immune response. 
IL-10 and TGF-β suppress IgE production and IL-10 induces inflammatory immunoglobulin isotype, IgG4. These two cytokines directly suppress allergic inflammation 
induced by effector cells such as mast cells, basophils and eosinophils. TReg cells influence the generation of dendritic cells and promote the development of IL-10-
producing dendritic cells. In addition, TReg cells inhibit Th2 cells, which can no longer provide cytokines such as IL-3, IL-4, IL-5, and IL-9. These cytokines are required 
for the differentiation, survival and activity of mast cells, basophils, eosinophils and mucus producing cells, as well as for the tissue homing of Th2 cells.
SIT, specific immunotherapy; SLIT, sublingual immunotheraphy; SCIT, subcutaneous immunotheraphy; Treg, T regulatory cells.
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10-producing Tr1 cells increased with supporting the role of 
Treg cells in the induction of allergen-specific tolerance in the 
humans.105 A very recent study showed that SIT with grass pol-
len extract leads to an increase in Foxp3+ cells in the sublingual 
epithelium.113
Treg cells and antibody response in allergen-SIT
B cell activation and antibody production is an essential event 
during an immune response to antigens. Mature B cells show 
antibody class-switching in response to antigenic stimulation 
and costimulatory signals.114 Isotype class-switching of B cells 
depends mainly on cytokines released from T helper cells. In 
allergic immune response, Th2 cells secrete high amount of 
IL-4 and IL-13, which lead to ε-chain switching of B cells and 
the secretion of elevated levels of IgE. Other factors affecting the 
isotype swithing are CD40 and/or TLR stimulation. Even 
though peripheral T cell tolerance is rapidly induced after SIT, 
whether B cells tolerance takes place is still uncertain. Clinical 
data revealed that normal immune response to allergen results 
in increased production of allergen-specific IgE together with 
allergen-specific IgG4. In allergen-SIT, a transient increase in 
serum specific IgE115 is followed by gradual decrease over 
months or years of treatment. In addition, allergen-specific 
IgG4 and IgG1 subtypes of IgG antibody increase 10 to 100-fold 
in serum levels with successful allergen-SIT.49 Secreted IgG4 is 
thought to block the allergen before its binding and cross-link-
ing of the IgE on the surface FcεRI receptors of mast cells and 
basophils, and by this inhibits activation and release of media-
tors responsible for type I hypersensitivity. However, there is 
poor correlation between the amount of allergen-specific IgG 
and clinical protection. Consequently, it becomes important to 
measure the blocking activity of allergen-specific IgG4 as well 
as IgG1 instead of their serum levels. In a clinical study of SLIT 
with grass polen extract, it was shown that IgG1 and IgG4 levels 
as well as seasonal IgA1 and IgA2 levels are increased.113 Also in 
this study, there is significant inhibition IgE-faciliated allergen 
binding to B cells at peak season, and time dependent increase 
in serum inhibitory activity for IgE-FAb in SLIT-treated atopic 
individuals.
IL-10 secreted from regulatory cells has a sophisticated role 
on the immune response with downregulation of T cells and 
induction of allergen-specific IgG4 antibodies. IL-10 counter-
regulates allergen-specific IgE vs IgG4 levels.28,101 Thus, IL-10 
regulates tolerance in T cells as well as inducing the IgG4 iso-
type rather than IgE phenotype. Clinical studies manifest dur-
ing allergen SIT to sensitized patients, although there is no sig-
nificant change in specific IgE levels, there is significant increase 
in specific IgA, IgG1, and IgG4 levels.31 Further studies also 
showed the correlation between increase of IgA and TGF-β and 
between increase of IgG4 and IL-10 in peripheral mucosal re-
sponse to allergens in healthy individuals as well as patients 
treated with allergen-SIT.31,40 During allergen-SIT IgE/IgG4 ratio 
decreases and this is associated with a change from allergen-
specific Th2 to Treg cell predominance. The change in IgE/IgG4 
ratio is observed almost after several weeks due to early increase 
in IgG4.28 This is probably due to long living IgE plasma cells in 
the bone marrow. Significant decrease in IgE levels occurs in 
years in spite of early generation of Treg cells. Overall, allergen-
SIT has immunomodulatory effect on antigen-specific T cells 
and B cells, and leads to early remission of clinical and late-
phase responses with a switch towards IgG4 in allergen-specif-
ic antibody levels.
CONCLUSION
In this review, we discussed the recent developments and 
more established knowledge on mechanisms of allergen-SIT. 
Peripheral T-cell tolerance is the key immunologic mechanism 
in the healthy immune response to self and non-infectious, non-
self antigens. Induction of peripheral T cell tolerance by Treg 
cells is the main event that takes place in successful allergen-
SIT. It is characterized by induction of Treg cells, suppressive 
cytokines such as IL-10 and also non-inflammatory antibody 
isotypes including IgG4 and IgA are essential to overcome aller-
gic state. Knowledge of this molecular basis is pivotal in under-
standing the equilibrated regulation of the immune response 
and unresponsiveness to immunologic agents and their possi-
ble therapeutic applications. A crucial area for future studies is 
the identification of drugs, cytokines, or costimulatory mole-
cules that induce peripheral T cell tolerance to environmental 
allergens. Novel vaccines that shorten the duration, decrease 
side effects, increase efficiency for treatment as well as novel 
preventive approach are expected due better understanding 
the mechanism of immune tolerance.
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